

# UCSF

## UC San Francisco Previously Published Works

### Title

Weight loss does not decrease risk of breast cancer-related arm lymphedema.

### Permalink

<https://escholarship.org/uc/item/6k82v5ps>

### Journal

Cancer, 127(21)

### ISSN

0008-543X

### Authors

Roberts, Sacha A  
Gillespie, Tessa C  
Shui, Amy M  
[et al.](#)

### Publication Date

2021-11-01

### DOI

10.1002/cncr.33819

Peer reviewed



Published in final edited form as:

Cancer. 2021 November 01; 127(21): 3939–3945. doi:10.1002/cncr.33819.

## Weight loss does not decrease risk of breast cancer-related arm lymphedema

Sacha A. Roberts, BS<sup>1</sup>, Tessa C. Gillespie, BS<sup>1</sup>, Amy M. Shui, MA<sup>2</sup>, Cheryl L. Brunelle, PT, MS, CCS, CLT<sup>3</sup>, Kayla M. Daniell, BS<sup>1</sup>, Joseph J. Locascio, PhD<sup>2</sup>, George E. Naoum, MD, MMSc<sup>1</sup>, Alphonse G. Taghian, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston MA, 02114

<sup>2</sup>Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston MA, 02114

<sup>3</sup>Department of Physical and Occupational Therapy, Massachusetts General Hospital, Boston MA, 02114

### Abstract

**Background:** The goal of this study was to determine the relationship between postoperative weight change and breast cancer-related lymphedema.

**Methods:** In this cohort study, 1,161 women underwent unilateral breast surgery for breast cancer from 2005 to 2020 and were prospectively screened for breast cancer-related lymphedema. Arm volume measurements were obtained via an optoelectronic perometer preoperatively, postoperatively, and in the follow-up setting every 6–12 months. Mean follow-up from preoperative baseline was 49.1 months. The main outcome was breast cancer-related lymphedema, defined as a relative volume change of the ipsilateral arm of  $\geq 10\%$  at least 3 months after surgery.

**Results:** 92 patients (7.9%) developed breast cancer-related lymphedema. Net weight loss vs. net weight gain from baseline to last follow-up was not protective against developing BCRL (HR 1.38; 95% CI 0.89 – 2.13;  $p=0.152$ ).

**Conclusion:** Although weight loss may be recommended as part of an individualized lifestyle management program for overall health, weight loss alone may not decrease the risk of developing BCRL.

### Precis:

---

**Corresponding author contact information:** Alphonse G. Taghian, MD, PhD, Professor of Radiation Oncology, Harvard Medical School, Department of Radiation Oncology, Director, Lymphedema Research Program, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, Tel: 617-726-7559, Fax: 617-726-3603, ATAGHIAN@mgh.harvard.edu.

**Author Contributions Statement:** TCG helped with study design and manuscript writing; AMS helped with statistical analyses; CLB helped with study design and manuscript writing; KMD helped with study design and manuscript writing; GEN helped with study design and statistical analyses; AGT is the senior author. Roberts helped with study design and manuscript writing, Locascio helped with statistical analyses, Taghian helped with study design and manuscript writing.

**Conflict of Interest Statement:** Alphonse Taghian is on the Scientific Advisory Board of Puretech Health and a previous Consultant in VisionRT. AGT has been loaned equipment from ImpediMed for use in investigator-initiated clinical trials. Cheryl Brunelle is on the Scientific Advisory Board of Puretech Health. These associations are unrelated to this manuscript. For the remaining authors none were declared.

Weight loss, when compared to weight gain, does not decrease the risk of BCRL (HR 1.38; 95% CI 0.89 – 2.13;  $p=0.152$ ).

## Keywords

Breast cancer; breast cancer-related lymphedema; lymphedema; weight change

## Background

Advancements in breast cancer (BC) diagnosis and treatment have dramatically increased long-term survival in recent years<sup>1</sup>. As a result, there is a growing need to better understand how BC treatments affect patients throughout survivorship. One significant complication of BC treatment is breast cancer-related lymphedema (BCRL); approximately one in five individuals treated for BC will develop BCRL<sup>2</sup>. BCRL results from protein-rich fluid accumulating in the interstitial space, leading to regional swelling<sup>3</sup>. Patients treated for BC are at lifelong risk of developing BCRL, which is an incurable disease that necessitates stressful, time-consuming and expensive treatment<sup>4</sup>. Because of the significant impact that BCRL has on patient quality of life, understanding the causes of this disease has become increasingly important.

Various studies have identified risk factors of BCRL, such as axillary lymph node dissection (ALND)<sup>3,5–10</sup>, number of positive lymph nodes<sup>3,5–8,11</sup>, regional lymph node irradiation (RLNR)<sup>3,9–13</sup>, being overweight (BMI  $\geq 25$  kg/m<sup>2</sup>) or obese (BMI  $\geq 30$  kg/m<sup>2</sup>) at breast cancer diagnosis<sup>3,5,17,6,8–11,14–16</sup> and cellulitis<sup>8–10,18,19</sup>. BCRL risk is lifelong, and timing of highest risk of BCRL development depends on BC treatment received. For example, peak BCRL risk is later for those who undergo SLNB than those who undergo ALND (36–48 months vs. 6–24 months post-operatively)<sup>2</sup>. While a high preoperative BMI is a well-established risk factor, the impact of overall postoperative weight loss or gain is unknown. Of the few studies that have analyzed the relationship between postoperative weight change and BCRL, they are limited by small sample size<sup>8</sup>, self-reported lymphedema<sup>6,8</sup>, self-reported weight/BMI<sup>8</sup>, retrospective assessment of lymphedema<sup>8</sup>, lack of presurgical baseline arm volumes<sup>6,8,20</sup>, and failure to assess the effect of weight loss and weight gain separately<sup>6,16,20</sup>. Because of these shortcomings, we sought to assess the impact of net weight loss vs. net weight gain on BCRL development in our cohort of 1,161 women who experienced a weight change.

## Methods

### Lymphedema assessments

At Massachusetts General Hospital, patients diagnosed with breast cancer are prospectively screened for BCRL. To screen for and diagnose BCRL, we consider objective arm volume measurements in tandem with patient-reported outcome measures and clinical examinations. To obtain objective arm measurements, we utilize an optoelectronic Perometer. The Perometer uses infrared light beams to measure arm volume, which has been demonstrated to be a reliable and valid way to measure the arm and thus assess lymphedema<sup>21–23</sup>.

Our group's measurement and screening protocol has been previously published<sup>24</sup>. Patients undergo bilateral arm measurements preoperatively, postoperatively, and every 6–12 months coinciding with their oncology follow-up visits. We strive to screen patients for as long as possible, with a current median follow-up time of 32 months.

To quantify arm volume changes, we utilize the relative volume change (RVC) equation<sup>25</sup>. The RVC assesses changes in the ipsilateral arm since preoperative baseline while controlling for any changes in volume of the contralateral arm. In short, the  $RVC = [(A_2U_1 / (U_2A_1)) - 1]$ , where  $A_1$  and  $A_2$  are the ipsilateral arm volumes at preoperative (baseline) and postoperative assessments, respectively, and  $U_1$  and  $U_2$  are the contralateral arm volumes at preoperative and postoperative assessments, respectively. In this study, BCRL was defined as an RVC  $\geq 10\%$  occurring  $\geq 3$  months after definitive breast surgery. Patients were censored after development of BCRL.

### Patient population

From 2005 to 2020, patients undergoing treatment for primary BC were screened for BCRL. All women were recruited at the time of initial presurgical consultation in our multidisciplinary breast oncology clinic. Each patient had a preoperative bilateral arm measurement, at least one postoperative bilateral arm measurement  $\geq 3$  months after surgery, and a weight recorded at the preoperative visit and all postoperative visits. Women who underwent bilateral breast surgery were excluded from analysis, providing us with a cohort of 1,409 patients. However, the 67 women who maintained weight from preoperative baseline to last follow up were removed as the primary aim of the study was to examine effect of weight gain or loss. Additionally, patients with ductal carcinoma in situ (DCIS) (n=175) or stage IV breast cancer (n=6) were excluded, resulting in a cohort of 1,161 women. In this cohort, 649 (55.9%) experienced a net weight gain from preoperative baseline to last follow-up (weight at last follow up was greater than preoperative weight) while 512 (44.1%) experienced a net weight loss (weight at last follow up was less than preoperative weight). For those who developed BCRL, last follow-up was defined as the visit in which the patient developed BCRL. For those who did not develop BCRL, last follow-up was defined as the last visit.

### Statistical Methods

Chi Square tests, t-tests, and Wilcoxon rank-sum tests were used, as appropriate, to compare categorical and continuous treatment-related risk factors between the cohort of patients who lost weight and those who gained weight. Univariate Cox proportional hazards regression models were performed on the BCRL outcome for the net weight change variable and for each potential covariate. Covariates included preoperative age, race (white vs. non-white), preoperative BMI, surgery type, nodal surgery type, RLNR, and adjuvant chemotherapy. Women were excluded if BCRL (defined as RVC  $\geq 10\%$   $\geq 3$  months after definitive breast surgery) occurred before receipt of RLNR or adjuvant chemotherapy. If a covariate was significant ( $p < 0.05$ ) in the unadjusted analysis, it was included in the subsequent multivariable model with the rate of weight change variable.

The multivariable model was assessed with the Kolmogorov-type supremum test, based on cumulative sums of martingale residuals, using a significance threshold of 0.01. Kaplan-Meier survival curves were generated in the two cohorts and a log-rank test was used to determine if there was a statistically significant difference in BCRL-free survival between the two groups. Hypothesis tests were two-sided, and the significance threshold was set to 0.05. All statistical analyses were performed using SAS/STAT version 9.4.

## Results

### Demographics

From 2005 to 2020, 1,161 patients underwent unilateral breast cancer surgery, were prospectively screened for BCRL, and experienced a weight change from preoperative baseline to their last follow-up. Among these women, 92 (7.9%) developed breast cancer-related lymphedema. The median time to onset of lymphedema was 18.5 months after definitive breast surgery (range: 3.0 to 115.0 months). The mean net weight change experienced by the 92 women who developed BCRL was -1.25 lbs (range: -31 to 29 lbs). The mean BMI at baseline for the entire cohort was 26.6 kg/m<sup>2</sup>, while the mean weight was 155 pounds. Regarding treatment, 28.1% underwent ALND, 32.0% underwent RLNR, and 39.3% received adjuvant chemotherapy. Demographic and treatment-related variables are further described and compared in the cohort of women who gained weight (n=649) vs. those who lost weight (n=512). The two cohorts differed in terms of net weight change, preoperative weight, BMI, and age. The mean (range) weight change from preoperative baseline to last follow-up was +8.2 lbs (+0.1 to +49.0) for those who gained weight and -8.7 lbs (-81.0 to -0.1) for those who lost weight (Table 1).

### Impact of Net Weight Change on BCRL

We assessed the impact of net weight loss (from preoperative baseline to last follow-up) vs. net weight gain on BCRL development (n=1,161). When controlling for type of surgery (mastectomy vs. lumpectomy), nodal surgery type (ALND vs. SLNB and ALND vs. no nodal surgery), RLNR, and adjuvant chemotherapy, net weight loss, when compared to net weight gain, was not protective against BCRL development (HR 1.38; 95% CI 0.89 – 2.13; p=0.152). Additionally, the Kaplan-Meier survival curve demonstrates that the BCRL-free survival in the cohort of women who lost weight is not significantly different from the BCRL-free survival of those who gained weight (p = 0.077) (Figure 1).

## Discussion

Although a high preoperative BMI is a well-established risk factor for BCRL, little is known regarding the relationship between overall weight changes and BCRL development. Women undergoing treatment for breast cancer often experience significant weight changes throughout and beyond BC treatment<sup>26,27,36,28-35</sup>. Therefore, we analyzed data from a cohort of 1,161 women who were treated for primary breast cancer. To our knowledge, this is the largest cohort study investigating the relationship between net weight change and BCRL development. In addition to the large sample size, this study utilized preoperative

assessments on all patients, objective measures of arm volume, weight measurements at all visits, and a mean follow-up of 49.1 months.

Our main findings suggest that weight loss does not decrease the risk of BCRL (Table 2). This counteracts the belief held by some that weight loss may be protective against developing BCRL. This belief may have been perpetuated as being overweight or obese at time of BC diagnosis is a risk factor for BCRL<sup>3,5,17,6,8-11,14-16</sup>. Given this, the hypothesis amongst some clinicians and researchers is that losing weight would therefore be protective against BCRL development. To our knowledge, there have been three studies examining the effect of weight loss in women with BCRL, two of which found a beneficial effect of weight loss on BCRL outcomes<sup>37-39</sup>. However, note that these cohorts already developed BCRL, as opposed to being at-risk for BCRL. Shaw et al found a significant correlation between weight loss and a reduction in excess arm volume ( $r: 0.423$ ;  $P = .002$ ) in 64 women with BCRL randomized to weight reduction through diet or to control group<sup>38</sup>. In another study by the same group analyzing data from 21 women with BCRL randomized to oral or written dietary advice vs control, there was a significant reduction in swollen arm volume at the end of the 12-week period ( $P = .003$ )<sup>37</sup>. Conversely, results from the Women in Steady Exercise Research (WISER) randomized clinical trial suggest that weight loss does not decrease arm volume difference in patients with BCRL<sup>39</sup>. In this study, 351 overweight breast cancer survivors with BCRL were randomized to one of four groups: control group, exercise group, weight loss group, or combined exercise and weight loss group. The authors found that engagement in 12 months of an exercise or weight loss program did not have an effect on BCRL outcomes.

Two other studies have examined the effect of weight gain or fluctuation on BCRL development in cohorts at risk, however, both studies carry significant limitations. In a previous study by our team, postoperative weight fluctuation data from 787 patients undergoing treatment for BC was analyzed in a retrospective cohort study<sup>16</sup>. Though this study was strong in terms of utilizing preoperative assessments, objective arm volume measurements, and having a large sample size, we did not assess weight gain separately from weight loss. In other words, we analyzed the effect of the absolute value of weight changes. We found that cumulative absolute fluctuation in weight from preoperative assessment significantly increased risk of developing BCRL on multivariable analysis. However, from this result, it remains unclear as to whether it was the weight gain, weight loss, or both, that increased risk of BCRL.

In one study that found an association between weight gain and BCRL development, 260 women treated for breast cancer were followed for 20 years, making this one of the longest-term follow-up studies in BCRL<sup>8</sup>. At 20 years postoperatively, the only factors found to be associated with BCRL were history of arm infection and post-treatment weight gain. No change in weight or weight loss was not found to be associated with BCRL. However, this study presents with significant limitations including but not limited to small sample size, lack of objective preoperative arm volume measurement, self-report of BCRL, and failure to assess weight fluctuations over time.

An imperative area of discussion is that weight loss in this study does not provide a protective effect on BCRL risk. This is a similar point to that made by the authors of the WISER trial<sup>39</sup>. Weight loss is recommended for patients who are overweight at breast cancer diagnosis, through diet and exercise interventions. Such weight loss imparts significant cardiovascular, pulmonary and musculoskeletal health benefits, and this should continue to be prioritized for these patients. However, the findings of this study suggest that these patients should also be screened vigilantly for BCRL, understanding that weight loss is not protective against BCRL. We may postulate that perhaps it is the improvement in tissue extensibility or decrease in fibrosis in the area of surgery, or improved kinematics of the shoulder with exercise that may impart a protective effect on BCRL risk. Further research is required in this area to better elucidate exercise effects which may protect patients from BCRL.

Of note, our study is not without limitations. Because all patients were screened for BCRL primarily at their naturally occurring oncology follow-up visits, patients were not measured at regular, pre-determined intervals. To most accurately determine the impact of postoperative weight fluctuations on BCRL risk, it would be imperative to weigh patients at frequent, regular intervals for at least five years postoperatively, considering the majority of cases of BCRL occur within the first five years postoperatively<sup>2</sup>. In addition to this major limitation, we did not collect information on the lifestyle habits of each patient throughout their treatment for breast cancer. This information would have been especially useful for the cohort of women who lost weight, as it may have helped to elucidate whether one's weight loss was attributed to healthy habits such as exercise, or if it was related to chemotherapy or other factors related to breast cancer management. A final yet significant limitation is that we were unable to assess the impact of weight maintenance on BCRL development due to the small number of patients (n=67) in this category.

It is imperative for providers to continue to prioritize overall health maintenance to maximize health outcomes after breast cancer treatment. This may include recommendation for weight loss in patients who are overweight, however, the clinician should be aware that weight loss is not protective against BCRL development. Screening for BCRL is imperative for early diagnosis and timely treatment, and weight changes should be incorporated with the goal of overall health maintenance rather than in an effort to protect against BCRL.

## Acknowledgements:

This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL1TR002541) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

## Funding Statement:

The project was supported by Award Number R01CA139118 (AG Taghian) and Award Number P50CA08393 (AG Taghian) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. This program is supported by the Adele McKinnon Research Fund for Breast Cancer-Related Lymphedema (AG Taghian), the Heinz Family Foundation (AG Taghian), and the Olayan-Xefos Family Fund for Breast Cancer Research (AG Taghian).




## References

1. American Cancer Society: Breast Cancer Facts & Figures. 2017–2018. <https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html>.
2. McDuff SGR, Mina AI, Brunelle CL, et al. Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk? *Int J Radiat Oncol Biol Phys*. 2019;103(1):62–70. doi:10.1016/j.ijrobp.2018.08.036 [PubMed: 30165125]
3. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis. *Lancet Oncol*. 2013;14(6):500–515. doi:10.1016/S1470-2045(13)70076-7 [PubMed: 23540561]
4. Fu MR. Breast cancer-related lymphedema: Symptoms, diagnosis, risk reduction, and management. *World J Clin Oncol*. 2014;5(3):241. doi:10.5306/wjco.v5.i3.241 [PubMed: 25114841]
5. Fu MR, Axelrod D, Guth AA, et al. Patterns of obesity and lymph fluid level during the first year of breast cancer treatment: A prospective study. *J Pers Med*. 2015;5(3):326–340. doi:10.3390/jpm5030326 [PubMed: 26404383]
6. SA M, MJ W, KT M, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. *J Clin Oncol*. 2008;26(32):5220–5226. doi:10.1200/JCO.2008.16.3766 [PubMed: 18838708]
7. Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. *Cancer Epidemiol Biomarkers Prev*. 2007;16(4):775–782. doi:10.1158/1055-9965.EPI-06-0168 [PubMed: 17416770]
8. Petrek JA, Senie RT, Peters M, Peterrosen P. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. *Cancer*. 2001;92(6):1368–1377. doi:10.1002/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9 [PubMed: 11745212]
9. Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. *Gland Surg*. 2018;7(4):379–403. doi:10.21037/gs.2017.11.04 [PubMed: 30175055]
10. Ferguson CM, Swaroop MN, Horick N, et al. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. *J Clin Oncol*. 2016;34(7):691–698. doi:10.1200/JCO.2015.61.5948 [PubMed: 26644530]
11. Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: A meta-analysis of treatment factors. *Ann Surg Oncol*. 2009;16(7):1959–1972. doi:10.1245/s10434-009-0452-2 [PubMed: 19365624]
12. Warren LEG, Miller CL, Horick N, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: A prospective cohort study. *Int J Radiat Oncol Biol Phys*. 2014;88(3):565–571. doi:10.1016/j.ijrobp.2013.11.232 [PubMed: 24411624]
13. Kilbreath SL, Refshauge KM, Beith JM, et al. Risk factors for lymphoedema in women with breast cancer: A large prospective cohort. *Breast*. 2016;28(2016):29–36. doi:10.1016/j.breast.2016.04.011 [PubMed: 27183497]
14. Wu R, Huang X, Dong X, Zhang H, Zhuang L. Obese patients have higher risk of breast cancer-related lymphedema than overweight patients after breast cancer: a meta-analysis. *Ann Transl Med*. 2019;7(8):172–172. doi:10.21037/atm.2019.03.44 [PubMed: 31168453]
15. Norman SA, Localio AR, Kallan MJ, et al. Risk factors for lymphedema after breast cancer treatment. *Cancer Epidemiol Biomarkers Prev*. 2010;19(11):2734–2746. doi:10.1158/1055-9965.EPI-09-1245 [PubMed: 20978176]
16. Jammallo LS, Miller CL, Singer M, et al. Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. *Breast Cancer Res Treat*. 2013;142(1):59–67. doi:10.1007/s10549-013-2715-7 [PubMed: 24122390]
17. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study. *Breast Cancer Res Treat*. 2011;130(3):981–991. doi:10.1007/s10549-011-1667-z [PubMed: 21761159]
18. Vignes S, Arrault M, Dupuy A. Factors associated with increased breast cancer-related lymphedema volume. *Acta Oncol (Madr)*. 2007;46(8):1138–1142. doi:10.1080/02841860701403020



19. Bevilacqua JLB, Kattan MW, Changhong Y, et al. Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer. *Ann Surg Oncol*. 2012;19(8):2580–2589. doi:10.1245/s10434-012-2290-x [PubMed: 22395997]
20. Goldberg JI, Wiechmann LI, Riedel ER, Morrow M, Van Zee KJ. Morbidity of sentinel node biopsy in breast cancer: The relationship between the number of excised lymph nodes and lymphedema. *Ann Surg Oncol*. 2010;17(12):3278–3286. doi:10.1245/s10434-010-1155-4 [PubMed: 20574774]
21. Lee MJ, Boland RA, Czerniec S, Kilbreath SL. Reliability and concurrent validity of the perometer for measuring hand volume in women with and without lymphedema. *Lymphat Res Biol*. 2011;9(1):13–18. doi:10.1089/lrb.2010.0021 [PubMed: 21417763]
22. Hidding JT, Viehoff PB, Beurskens CHG, van Laarhoven HWM, Nijhuis-van der Sanden MWG, van der Wees PJ. Measurement Properties of Instruments for Measuring of Lymphedema: Systematic Review. *Phys Ther*. 2016;96(12):1965–1981. doi:10.2522/ptj.20150412 [PubMed: 27340195]
23. Stanton AWB, Northfield JW, Holroyd B, Mortimer PS, Levick JR. Validation of an optoelectronic limb volumeter (perometer). *Lymphology*. 1997;30(2):77–97. [PubMed: 9215977]
24. Brunelle C, Skolny M, Ferguson C, Swaroop M, O'Toole J, Taghian AG. Establishing and sustaining a prospective screening program for breast cancer-related lymphedema at the Massachusetts general hospital: Lessons learned. *J Pers Med*. 2015;5(2):153–164. doi:10.3390/jpm5020153 [PubMed: 26011383]
25. Ancukiewicz M, Russell TA, O'toole J, et al. Standardized method for quantification of developing lymphedema in patients treated for breast cancer. *Int J Radiat Oncol Biol Phys*. 2011;79(5):1436–1443. doi:10.1016/j.ijrobp.2010.01.001 [PubMed: 20605339]
26. Schwartz AL. Exercise and weight gain in breast cancer patients receiving chemotherapy. *Cancer Pract*. 2000;8(5):231–237. doi:10.1046/j.1523-5394.2000.85007.x [PubMed: 11898235]
27. Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: Evidence from the women's healthy eating and living (WHEL) study. *Breast Cancer Res Treat*. 2007;105(2):177–186. doi:10.1007/s10549-006-9442-2 [PubMed: 17123151]
28. Villarini A, Pasanisi P, Raimondi M, et al. Preventing weight gain during adjuvant chemotherapy for breast cancer: A dietary intervention study. *Breast Cancer Res Treat*. 2012;135(2):581–589. doi:10.1007/s10549-012-2184-4 [PubMed: 22869285]
29. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. *J Clin Oncol*. 2005;23(7):1370–1378. doi:10.1200/JCO.2005.01.079 [PubMed: 15684320]
30. Irwin ML, McTiernan A, Baumgartner RN, et al. Changes in body fat and weight after a breast cancer diagnosis: Influence of demographic, prognostic, and lifestyle factors. *J Clin Oncol*. 2005;23(4):774–782. doi:10.1200/JCO.2005.04.036 [PubMed: 15681521]
31. Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer - effect of tamoxifen. *Breast Cancer Res Treat*. 1992;22(2):129–132. doi:10.1007/BF01833342 [PubMed: 1391977]
32. Goodwin PJ. Weight gain in early-stage breast cancer: Where do we go from here? *J Clin Oncol*. 2001;19(9):2367–2369. doi:10.1200/JCO.2001.19.9.2367 [PubMed: 11331314]
33. Chen X, Lu W, Zheng W, et al. Obesity and weight change in relation to breast cancer survival. *Breast Cancer Res Treat*. 2010;122(3):823–833. doi:10.1007/s10549-009-0708-3 [PubMed: 20058068]
34. Caan BJ, Kwan ML, Hartzell G, et al. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. *Cancer Causes Control*. 2008;19(10):1319–1328. doi:10.1007/s10552-008-9203-0 [PubMed: 18752034]
35. Berg MMGA, Winkels RM, Kruif JTCM, et al. Weight change during chemotherapy in breast cancer patients: A meta-analysis. *BMC Cancer*. 2017;17(1). doi:10.1186/s12885-017-3242-4
36. Atalay C, Kucuk AI. Effect of weight gain during adjuvant chemotherapy on survival in breast cancer. *Turkish J Surg*. 2015:124–127. doi:10.5152/ucd.2015.3123

37. Shaw C, Mortimer P, Judd PA. A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema. *Cancer*. 2007;110(8):1868–1874. doi:10.1002/cncr.22994 [PubMed: 17823909]
38. Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. *Cancer*. 2007;109(10):1949–1956. doi:10.1002/cncr.22638 [PubMed: 17393377]
39. Winkels RM, Sturgeon KM, Kallan MJ, et al. The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema. *Contemp Clin Trials*. 2017;61(5 2017):63–72. doi:10.1016/j.cct.2017.07.017 [PubMed: 28739540]



**Figure 1.** Kaplan-Meier curves displaying the predicted percentage of patients still BCRL-free at various times since surgery, for patients who had an overall net weight gain from baseline to last follow-up and for patients who had an overall net weight loss from baseline to last follow-up. Abbreviations: BCRL = breast cancer-related lymphedema.

**Table 1.**

## Demographics and treatment-related characteristics

	Entire Cohort (n=1,161)	Gained Weight (n=649)	Lost Weight (n=512)	p-value
Preoperative weight (lbs) *	155 (92 – 340)	157.7 (92 – 340)	167.8 (97.5 – 322)	<0.001
Net weight change (lbs) *	--	8.2 (0.1 – 49.0)	-8.7 (-81.0 – -0.1)	<0.001
Preoperative BMI (kg/m <sup>2</sup> ) *	26.6 (15.8 – 58.9)	27.1 (15.8 – 58.4)	29.0 (18.4 – 58.9)	<0.001
Age (years) *	56.6 (27.0 – 85.9)	55.5 (27.2 – 85.9)	58.0 (27.0 – 82.3)	<0.001
Race				
White	1,042 (89.8%)	582 (89.8%)	460 (89.8%)	0.999
Non-white	118 (10.2%)	66 (10.2%)	52 (10.2%)	
Surgery				
Mastectomy	237 (20.4%)	137 (21.1%)	100 (19.5%)	0.556
Lumpectomy	924 (79.6%)	512 (78.9%)	412 (80.5%)	
Nodal surgery				
ALND	326 (28.1%)	192 (30.0%)	134 (26.2%)	0.304
SLNB	782 (67.4%)	425 (65.5%)	357 (69.7%)	
None	53 (4.6%)	32 (4.9%)	21 (4.1%)	
Lymph nodes sampled **	2 (0 – 43)	3 (0 – 41)	2 (1 – 43)	0.395
Lymph nodes malignant **	0 (0 – 39)	0 (0 – 39)	0 (0 – 32)	0.834
Breast cancer stage				
I	686 (59.1%)	388 (59.8%)	298 (58.2%)	
II	337 (29.0%)	193 (29.7%)	144 (28.1%)	
III	134 (11.5%)	68 (10.5%)	66 (12.9%)	0.405
Unknown	4 (0.3%)	--	4 (0.8%)	
RLNR	372 (32.0%)	209 (2.2%)	163 (31.8%)	0.944
Neoadjuvant chemotherapy	150 (12.9%)	89 (13.7%)	61 (11.9%)	0.520
Adjuvant chemotherapy	456 (39.3%)	255 (39.3%)	201 (39.3%)	0.999
Adjuvant hormonal therapy	932 (80.3%)	525 (80.9%)	407 (79.5%)	0.602
Maximum follow-up (months since baseline) *	49.1 (1.2, 178.2)	48.7 (1.2, 151.7)	49.5 (1.4, 178.2)	0.630
Developed BCRL	92 (7.9%)	43 (6.6%)	49 (9.6%)	0.083
Time to onset of BCRL (months since surgery) **	18.5 (3.0 – 115.0)	20.7 (3.0 – 110.2)	16.2 (3.4 – 115.0)	0.684

\* Mean or

\*\* median with (range) is shown.

p-value compares variables between those who gained weight vs. those who lost weight.

Abbreviations: body mass index (BMI); axillary lymph node dissection (ALND); sentinel lymph node biopsy (SLNB); regional lymph node radiation (RLNR); breast cancer-related lymphedema (BCRL).

**Table 2.**

Impact of weight change from preoperative baseline to last follow-up on BCRL development: multivariable analysis (n=1,161)

	Univariate		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Net weight loss vs. net weight gain	1.45 (0.96, 2.18)	0.078	1.38 (0.89, 2.13)	0.152
Baseline BMI (kg/m <sup>2</sup> )	1.04 (1.01, 1.07)	0.003	1.04 (1.01, 1.07)	0.005
Age at baseline (years)	1.01 (0.99, 1.03)	0.232	--	--
Race (white vs. non-white)	0.87 (0.44, 1.74)	0.701	--	--
Mastectomy vs. lumpectomy	2.49 (1.64, 3.80)	<0.001	1.02 (0.61, 1.70)	0.955
ALND vs. SLNB	4.47 (2.88, 6.95)	<0.001	2.77 (1.37, 5.60)	0.005
ALND vs. no nodal surgery	4.22 (1.03, 17.3)	0.045	2.41 (0.53, 10.9)	0.256
RLNR vs. no RLNR	4.08 (2.59, 6.42)	<0.001	2.47 (1.21, 5.04)	0.013
Adjuvant chemotherapy (+/- neoadjuvant chemotherapy) vs. no adjuvant chemotherapy	1.50 (0.99, 2.26)	0.055	0.66 (0.41, 1.05)	0.080

Abbreviations: BMI, body mass index; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; sx, surgery; RLNR, regional lymph node irradiation; HR, hazard ratio; CI, confidence interval.